An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will release its financial and operational results for Q1 2023 on May 4, 2023, before market opening. The management team will hold a conference call/webcast at 8:30 am ET to discuss these results and update the business. Interested participants can join by dialing (888) 645-4404 / (862) 298-0702, with a replay available on the company’s website thereafter.
Aurinia focuses on developing therapies for autoimmune, kidney, and rare diseases, with its flagship product being LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for active lupus nephritis introduced in January 2021. The company's headquarters are located in Edmonton, Alberta, with a U.S. commercial hub in Rockville, Maryland.
Positive
Scheduled release of Q1 2023 results may indicate potential growth in financial performance.
Aurinia's focus on therapies for high unmet medical needs positions it well in the biopharmaceutical market.
Negative
The upcoming results release may reflect challenges in revenue growth or market performance.
EDMONTON, Alberta--(BUSINESS WIRE)--
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the first quarter of 2023, on Thursday, May 4, 2023, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update. Interested participants can dial (888) 645-4404 / (862) 298-0702 (Toll-free U.S. & Canada). The audio webcast can also be accessed under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Edmonton, Alberta, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.
